Fouda, Genevieve G <br/><br/>
Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.  [electronic resource] 

 -  The Journal of infectious diseases  Feb 2015 
 - 508-17 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1537-6613 
<br/><br/><label>Standard No.: </label>10.1093/infdis/jiu444  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AIDS Vaccines--administration & dosage<br/>HIV Antibodies--blood<br/>HIV Envelope Protein gp120--immunology<br/>HIV Infections--prevention & control<br/>HIV-1--immunology<br/>Humans<br/>Immunoglobulin A--blood<br/>Immunoglobulin G--blood<br/>Infant<br/>Infant, Newborn<br/>Retrospective Studies